Telomerase targeting drug demonstrates benefit in myelofibrosis treatment

ROCHESTER, Minn. — Imetelstat, a novel drug that targets telomerase, has demonstrated potential value in treating patients with myelofibrosis, according to the results of a study published today in the New England Journal of Medicine.

"We observed that Imetelstat was active and induced morphologic and molecular remissions in some patients with myelofibrosis," says Ayalew Tefferi, M.D., a hematologist at Mayo Clinic and lead author of the study. "We also observed that Imtelstat demonstrated selective anti-clonal activity, inhibiting the growth of cancer cells, which we had not previously documented with other drugs."

MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

Journalists: Sounds bites with Dr. Tefferi are available in the downloads.

Myelofibrosis is a chronic myeloid cancer in which bone marrow cells that produce blood cells develop and function abnormally. The result is the formation of scar tissue in the bone marrow (fibrosis), severe anemia that often requires transfusion, weakness, fatigue, and an enlarged spleen and liver. Patients with myelofibrosis harbor one of several genetic mutations in their blood stem cells, including JAK2, MPL, CALR, ASXL1 and spliceosome pathway mutations."Typically, myelofibrosis is characterized by marrow scarring, and, although patients may derive symptomatic relief from other treatments, such as ruxolitinib, they usually do not revert back to normal bone marrow," Dr. Tefferi says. "Some patients treated with Imetelstat have reverted back to normal bone marrow." Imetelstat works by inhibiting telomerase activity in tumor cells, which leads to cell death.

Researchers studied 33 patients with a median age of 67 years. Nearly half of those patients had received prior treatment with a JAK inhibitor. Researchers noted a complete or partial remission in seven patients. The median duration of complete response was 18 months. Bone marrow fibrosis was reversed in all four patients who experienced a complete response, and a molecular response was documented in three of the four patients.

"We noted a difference in response rates, especially in complete remission rates, in patients with and without certain specific gene mutations, such as ASXL1, SF3B1 and U2AF1, says Dr. Tefferi. "This underscores the need for laboratory correlative studies in future clinical trials."

Treatment-related adverse events included thrombocytopenia, neutropenia, anemia and elevation in liver function enzyme levels.

Funding for the study was provided by Geron Corporation.

Co-authors include:

• Terra L. Lasho, Ph.D., Mayo Clinic
• Kebede H. Begna, M.D., 
Mayo Clinic
• Mrinal M. Patnaik, M.D., Mayo Clinic
• Darci L. Zblewski, A.P.R.N., C.N.P.,
Mayo Clinic
• Christy M. Finke, Mayo Clinic
• Lauren Schimek, B.S., Mayo Clinic
• Curtis A. Hanson, M.D., Mayo Clinic
• Naseema Gangat, M.D., Mayo Clinic
• Animesh Pardanani, M.D., Ph.D., Mayo Clinic
• Rebecca R. Laborde, Ph.D., Mayo Clinic
• Emnet Wassie, M.D., Mayo Clinic
• Xiaolin Wang, Ph.D., Geron Corporation

About the Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, the Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 1-855-776-0015 (toll-free).

###

About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.org and http://www.mayoclinic.org/news.